A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management

References

• Zavaleta EG, Fernandez BB, Grove MK, Kaye MD. St. Anthony’s fire (ergotamine induced leg ischemia)—a case report and review of the literature. Angiology. 2001;52: 349–56.
   PubMed Web of Science ®Google Scholar
• Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: The Rotterdam study. Arch Intern Med. 2000;160: 2934–8.
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, . ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47: 1239–312.
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, . Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, . Heart disease and stroke statistics—2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–171.
   PubMed Web of Science ®Google Scholar
• Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71: 510–5.
   PubMed Web of Science ®Google Scholar
• Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med. 1996;1:60–4.
   PubMedGoogle Scholar
• Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, . Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review. Circulation. 1996;94:3026–49.
   PubMed Web of Science ®Google Scholar
• Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol. 1998;18:185–92.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, . International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–9.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Mehta S, Liu K, Guralnik JM, Martin GJ, Criqui MH, . Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Intern Med. 1999;14:173–81.
   PubMedGoogle Scholar
• McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med. 1999;159: 387–92.
   PubMedGoogle Scholar
• McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, . Leg symptoms in peripheral arterial disease: Associated clinical characteristics and functional impairment. JAMA. 2001;286:1599–606.
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1–75.
   PubMedGoogle Scholar
• Collins TC, Beyth RJ, Nelson DB, Petersen NJ, Suarez-Almazor ME, Bush RL, . Process of care and outcomes in patients with peripheral arterial disease. J Gen Intern Med. 2007;22:942–8.
   PubMedGoogle Scholar
• Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA. 1993;270:487–9.
   PubMed Web of Science ®Google Scholar
• Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: How peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3:241–5.
   PubMedGoogle Scholar
• Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: Morbidity and mortality implications. Circulation. 2006;114:688–99.
   PubMed Web of Science ®Google Scholar
• Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, . Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–6.
   PubMed Web of Science ®Google Scholar
• Criqui MH. Peripheral arterial disease—epidemiological aspects. Vasc Med. 2001;6:3–7.
   PubMed Web of Science ®Google Scholar
• McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991;87:119–28.
   PubMed Web of Science ®Google Scholar
• Beaglehole R, Irwin A, Prentice T. The world health report 2004—changing history. Geneva, Switzerland: World Health Organization. 2004.
   Google Scholar
• Hebert K, Lopez B, Macedo FY, Gomes CR, Urena J, Arcement LM. Peripheral vascular disease and erectile dysfunction as predictors of mortality in heart failure patients. J Sex Med. 2009;6:1999–2007.
   PubMedGoogle Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Wilson PW, D’Agostino R Sr, Ohman EM, Rother J, . One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–206.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Guralnik JM, Ferrucci L, Tian L, Liu K, Liao Y, . Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation. 2008;117: 2484–91.
   PubMed Web of Science ®Google Scholar
• Leng GC, Lee AJ, Fowkes FGR, Whiteman M, Dunbar J, Housely E, . Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172–81.
   PubMed Web of Science ®Google Scholar
• McLafferty RB, Dunnington GL, Mattos MA, Markwell SJ, Ramsey DE, Henretta JP, . Factors affecting the diagnosis of peripheral vascular disease before vascular surgery referral. J Vasc Surg. 2000;31:870–9.
   PubMedGoogle Scholar
• English JA, Carell ES, Guidera SA, Tripp HF. Angiographic prevalence and clinical predictors of left subclavian stenosis in patients undergoing diagnostic cardiac catheterization. Catheter Cardiovasc Interv. 2001;54:8–11.
   PubMed Web of Science ®Google Scholar
• Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in ‘t Veld AJ, Schalekamp MA, Habbema JD. A clinical prediction rule for renal artery stenosis. Ann Intern Med. 1998;129:705–11.
   PubMedGoogle Scholar
• Spertus J, Jones P, Poler S, Rocha-Singh K. The peripheral artery questionnaire: A new disease-specific health status measure for patients with peripheral arterial disease. Am Heart J. 2004;147:301–8.
   PubMed Web of Science ®Google Scholar
• Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol. 1988;17:248–54.
   PubMed Web of Science ®Google Scholar
• Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–21.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, . Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis. JAMA. 2008;300: 197–208.
   PubMed Web of Science ®Google Scholar
• Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, . Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993;88:837–45.
   PubMed Web of Science ®Google Scholar
• Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA. 1993;270:465–9.
   PubMed Web of Science ®Google Scholar
• Zheng ZJ, Sharrett AR, Chambless LE, Rosamond WD, Nieto FJ, Sheps DS, . Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 1997;131:115–25.
   PubMed Web of Science ®Google Scholar
• Sikkink CJ, van Asten WN, van ‘t Hof MA, van Langen H, van der Vliet JA. Decreased ankle/brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease. Vasc Med. 1997;2:169–73.
   PubMedGoogle Scholar
• Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, . Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25:17–24.
   PubMed Web of Science ®Google Scholar
• Morillas P, Cordero A, Bertomeu V, Gonzalez-Juanatey JR, Quiles J, Guindo J, . Prognostic value of low ankle-brachial index in patients with hypertension and acute coronary syndromes. J Hypertens. 2009;27:341–7.
   PubMed Web of Science ®Google Scholar
• Ramos R, Quesada M, Solanas P, Subirana I, Sala J, Vila J, . Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk. Eur J Vasc Endovasc Surg. 2009;38:305–11.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Cambou JP, Kownator S, Belliard JP, Beregi JP, Branchereau A, . Prevalence of peripheral arterial disease in high-risk patients using ankle-brachial index in general practice: A cross-sectional study. Int J Clin Pract. 2009; 63:63–70.
   PubMed Web of Science ®Google Scholar
• Lange SF, Trampisch HJ, Pittrow D, Darius H, Mahn M, Allenberg JR, . Profound influence of different methods for determination of the ankle brachial index on the prevalence estimate of peripheral arterial disease. BMC Public Health. 2007;7:147.
   PubMedGoogle Scholar
• Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Savvidis S, Messow CM, . Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation. 2008;118:961–7.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Housley E, Macintyre CC, Prescott RJ, Ruckley CV. Variability of ankle and brachial systolic pressures in the measurement of atherosclerotic peripheral arterial disease. J Epidemiol Community Health. 1988;42:128–33.
   PubMed Web of Science ®Google Scholar
• Nicolaï SP, Kruidenier LM, Rouwet EV, Bartelink ML, Prins MH, Teijink JA. Ankle brachial index measurement in primary care: Are we doing it right? Br J Gen Pract. 2009;59: 422–7.
   PubMed Web of Science ®Google Scholar
• Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, . Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: The Strong Heart Study. Circulation. 2004;109: 733–9.
   PubMed Web of Science ®Google Scholar
• Wütschert R, Bounameaux H. Determination of amputation level in ischemic limbs. Reappraisal of the measurement of TcPo2. Diabetes Care. 1997;20:1315–8.
   PubMedGoogle Scholar
• Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ. 2004;171:1189–92.
   PubMed Web of Science ®Google Scholar
• The DCCT Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75:894–903.
   PubMedGoogle Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53.
   PubMed Web of Science ®Google Scholar
• Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108: 1481–6.
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, . Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.
   PubMed Web of Science ®Google Scholar
• Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.
   PubMed Web of Science ®Google Scholar
• Paravastu SC, Mendonca D, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2008;CD005508.
   Google Scholar
• Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: Ramipril markedly improves walking ability in patients with peripheral arterial disease: A randomized trial. Ann Intern Med. 2006;144:660–4.
   PubMed Web of Science ®Google Scholar
• Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens. 2008;26:1037–42.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–39.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001;358:527–33.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, . Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288:2411–20.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, . Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49: 1982–8.
   PubMed Web of Science ®Google Scholar
• Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003; 41: 62S–9S.
   PubMed Web of Science ®Google Scholar
• Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, . Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–27.
   PubMed Web of Science ®Google Scholar
• Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995;274:975–80.
   PubMed Web of Science ®Google Scholar
• Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2000;CD000990.
   Google Scholar
• Milani RV, Lavie CJ. The role of exercise training in peripheral arterial disease. Vasc Med. 2007;12:351–8.
   PubMed Web of Science ®Google Scholar
• Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, . A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041–50.
   PubMed Web of Science ®Google Scholar
• Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98: 678–86.
   PubMed Web of Science ®Google Scholar
• Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, . Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267–74; discussion 74–5.
   PubMed Web of Science ®Google Scholar
• Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, . Effect of cilostazol in patients with intermittent claudication: A randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002; 36:83–91.
   PubMedGoogle Scholar
• Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, . A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–30.
   PubMed Web of Science ®Google Scholar
• Mohler ER 3rd, Beebe HG, Salles-Cuhna S, Zimet R, Zhang P, Heckman J, . Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Vasc Med. 2001;6:151–6.
   PubMed Web of Science ®Google Scholar
• Chapman TM, Goa KL. Cilostazol: A review of its use in intermittent claudication. Am J Cardiovasc Drugs. 2003;3: 117–38.
   PubMedGoogle Scholar
• Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, . Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis. Arch Intern Med. 1999; 159:337–45.
   PubMed Web of Science ®Google Scholar
• Bianchi C, Montalvo V, Ou HW, Bishop V, Abou-Zamzam AM Jr. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg. 2007;21:163–6.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Hahn EA, Greenland P, Cella D, Ockene JK, Brogan D, . Atherosclerotic risk factor reduction in peripheral arterial disease: Results of a national physician survey. J Gen Intern Med. 2002;17:895–904.
   PubMed Web of Science ®Google Scholar